Portola Pharmaceuticals, Inc. (PTLA)
| Market Cap | 1.41B |
| Revenue (ttm) | 120.86M |
| Net Income (ttm) | -281.28M |
| Shares Out | 78.48M |
| EPS (ttm) | -3.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Jul 2, 2020 |
| Last Price | $18.03 |
| Previous Close | $18.03 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 17.99 - 18.07 |
| Day's Volume | 0 |
| 52-Week Range | 5.31 - 31.73 |
News
SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pand...
Portola Pharmaceuticals - This Name You Haven't Heard Of Is The Next Big COVID-19 Company
SOUTH SAN FRANCISCO, Calif., May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed exte...
Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of -18.92% and -26.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for...
Alexion Pharmaceuticals made a move to acquire Portola Pharmaceuticals.
Portola Pharmaceuticals Inc. (NASDAQ: PTLA) shares more than doubled on Tuesday after the company announced that it would be acquired by Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals pledged to buy Portola Pharmaceuticals on Tuesday in a deal that combines two blood disease-focused biotech companies. Alexion stock slipped, but Portola stock flew.
Portola Pharmaceuticals, Inc. (PTLA) CEO Scott Garland on Q4 2019 Results - Earnings Call Transcript
Portola Pharmaceuticals, Inc. (PTLA) CEO Scott Garland on Q4 2019 Results - Earnings Call Transcript
Investors need to pay close attention to Portola Pharmaceuticals (PTLA) stock based on the movements in the options market lately.
Portola: Still Bleeding, What I'm Looking For Before Buying It Back
Investors ran away after the business provided preliminary full-year 2019 results.
Shares of Portola Pharmaceuticals Inc. PTLA, -43.25% tumbled 45% in trading on Friday after the company shared "disappointing" preliminary fourth-quarter revenue for Andexxa, its antidote for ...
Stocks making the biggest moves after the bell: KB Home, Intuitive Surgical, NortonLifeLock and more
Take a look at the companies making headlines after the bell.
These three small companies have the potential to make you a lot of money.
If you want to see your investment in the biotech market grow two-fold, these are the top stocks to buy.
These three healthcare companies have a lot of good signs going for them.
Portola Pharmaceuticals' (PTLA) CEO Scott Garland on Q3 2019 Results - Earnings Call Transcript
Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 35.37% and 6.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead fo...
Portola Pharmaceuticals (PTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Portola has sidelined Bevyxxa after failing to secure its approval in Europe and focused its attention on Factor Xa reversal agent Andexxa.
What should investors think of this biotech stock and its signature drug candidate Andexxa?
The company's second-quarter revenue is sparking optimism for future growth.
Portola Pharmaceuticals, Inc. (PTLA) CEO Scott Garland on Q2 2019 Results - Earnings Call Transcript
Portola Pharmaceuticals, Inc. (PTLA) CEO Scott Garland on Q2 2019 Results - Earnings Call Transcript
Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 12.38% and 17.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for th...
Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Portola Pharmaceuticals' products present clinicians with many headaches, and the company's equity has been beaten down recently.
The company's still struggling to transition from clinical stage to commercial stage, but it's making progress.
Portola Pharmaceuticals' (PTLA) CEO Scott Garland on Q1 2019 Results - Earnings Call Transcript
First-quarter financial results are failing to spark investor optimism on concerns over cash burn.
Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 0.00% and 6.38%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the...
This commercial-stage company's success depends heavily on the demand for one drug.
Portola Pharmaceuticals is a growth company that is undergoing strong fundamentals development.
About PTLA
Portola Pharmaceuticals, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness. It also develops cerdulatinib, an investigational oral,... [Read more...]
| Industry Biotechnology | IPO Date May 22, 2013 |
| CEO J. Scott Garland | Employees 408 |
| Stock Exchange NASDAQ | Ticker Symbol PTLA |
Financial Performance
In 2019, PTLA's revenue was $116.64 million, an increase of 190.66% compared to the previous year's $40.13 million. Losses were -$290.66 million, -17.01% less than in 2018.